River Road Asset Management LLC Has $13.30 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

River Road Asset Management LLC increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 9.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 469,980 shares of the biopharmaceutical company's stock after buying an additional 41,918 shares during the quarter. River Road Asset Management LLC owned about 0.08% of Royalty Pharma worth $13,296,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Xponance Inc. lifted its holdings in shares of Royalty Pharma by 1.9% during the 2nd quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company's stock worth $836,000 after acquiring an additional 606 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Royalty Pharma by 32.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 655 shares during the last quarter. Values First Advisors Inc. boosted its holdings in shares of Royalty Pharma by 7.6% in the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company's stock valued at $295,000 after purchasing an additional 738 shares in the last quarter. Phillips Wealth Planners LLC boosted its holdings in shares of Royalty Pharma by 10.2% in the 3rd quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company's stock valued at $246,000 after purchasing an additional 808 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Royalty Pharma by 10.8% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company's stock valued at $276,000 after purchasing an additional 887 shares during the last quarter. Institutional investors own 54.35% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Citigroup reduced their price objective on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, October 25th. The Goldman Sachs Group raised their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a "buy" rating in a research note on Wednesday, August 14th. Morgan Stanley upped their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, July 11th. Finally, StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $41.67.

Royalty Pharma Trading Down 3.3 %

Shares of Royalty Pharma stock traded down $0.90 during trading on Wednesday, hitting $26.64. The company's stock had a trading volume of 4,598,826 shares, compared to its average volume of 2,572,745. The stock has a market cap of $15.81 billion, a price-to-earnings ratio of 23.58, a price-to-earnings-growth ratio of 4.00 and a beta of 0.47. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66. The stock has a 50-day moving average price of $27.93 and a two-hundred day moving average price of $27.56.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million during the quarter, compared to analysts' expectations of $600.83 million. During the same quarter in the prior year, the firm posted $0.85 earnings per share. Equities research analysts anticipate that Royalty Pharma plc will post 4.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.15%. Royalty Pharma's dividend payout ratio (DPR) is currently 74.34%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.